Commentary

Commentary

Tariffs Won’t Secure Our Drug Supply Chain—They’ll Break It

The Trump administration is considering massive “Section 232” tariffs on imported medicines from key U.S. allies, including the European Union, the United Kingdom, Switzerland, Japan, and South Korea. While tariffs on some countries, such as EU member states, could be capped at 15%, other tariffs could reportedly be set as ...
Commentary

The New Medicine Tariffs Are a Prescription for Disaster

President Trump has recently struck trade agreements with the European Union and Japan. Both deals will impose a 15 percent tariff on imported prescription drugs and active pharmaceutical ingredients. White House officials believe these tariffs will benefit Americans by nudging pharmaceutical companies to relocate their manufacturing operations stateside in order ...
Commentary

How innovation saves lives: What America’s pharmaceutical ecosystem gets right

When a woman is diagnosed with breast cancer in the United States today, her chances of surviving are much greater than in decades past — thanks to U.S. innovation. The incidence of breast cancer has increased by more than 200% globally in the past 40 years. But the U.S. mortality ...
Commentary

The rural hospital rescue fund is a fraud

Rural hospitals are supposedly in dire financial straits. And the forthcoming Medicaid “cuts” authorized by the One Big Beautiful Bill Act could put hundreds more facilities deep in the red. At least, that’s the prevailing narrative inside the beltway — and the justification for the $50 billion rural hospital “rescue” ...
Commentary

What’s The GLP-1 Black Market, How Big a Threat Is It?

A black market in weight-loss drugs is flourishing in plain sight. Rogue pharmacies and telehealth firms are flooding the United States with unauthorized knock-offs of semaglutide, tirzepatide, and other glucagon-like peptide-1 drugs. Better known by brand names like Ozempic, Wegovy, Mounjaro, and Zepbound, the knock-off versions of these drugs are ...
Commentary

Generics Must Compete On Price, Not Safety

America’s generic drug market is one of our greatest health policy successes. Today, 91% of all prescriptions in the U.S. are filled with generics. That dominance saves patients and taxpayers hundreds of billions of dollars every year—and it also drives innovation. Drugmakers know their monopoly on a new treatment will ...
Commentary

The Inflationary Effect of Drug Price Controls

In a bill chock full of bad policies, the drug pricing provision of the Inflation Reduction Act stands out as particularly troubling. This provision establishes a negotiation process to set a Maximum Fair Price (MFP) on selected drugs for Medicare patients. Because the legislation calls the MFP a negotiation doesn’t ...
Commentary

The Trump Administration Is Reviving Its Worst Drug Pricing Policies

It’s been a big year for revivals. There’s a new Jurassic Park movie, a reunion tour featuring 1990s rock band Oasis, and a Harry Potter television series in the works. President Trump is also looking to revive some of the policies he tried to enact during his first term. He ...
Commentary

Juvenile justice reforms drive a spike in criminal offenses

Juvenile crime in California is rising – and rising by a lot. Last year, the number of juveniles arrested for all types of offenses reached 32,874, which was a staggering increase of 70 percent from just a few years ago in 2021, and since 2019 juvenile homicides rose 82 percent. ...
Commentary

Is a Primary Care Revolution Dawning?

Americans in need of primary care will soon have more options, thanks to the One Big Beautiful Bill Act (OBBBA). The recently passed law allows patients to use money from tax-advantaged health savings accounts to pay for direct primary care for the first time. Direct primary care, or DPC, is ...
Commentary

Tariffs Won’t Secure Our Drug Supply Chain—They’ll Break It

The Trump administration is considering massive “Section 232” tariffs on imported medicines from key U.S. allies, including the European Union, the United Kingdom, Switzerland, Japan, and South Korea. While tariffs on some countries, such as EU member states, could be capped at 15%, other tariffs could reportedly be set as ...
Commentary

The New Medicine Tariffs Are a Prescription for Disaster

President Trump has recently struck trade agreements with the European Union and Japan. Both deals will impose a 15 percent tariff on imported prescription drugs and active pharmaceutical ingredients. White House officials believe these tariffs will benefit Americans by nudging pharmaceutical companies to relocate their manufacturing operations stateside in order ...
Commentary

How innovation saves lives: What America’s pharmaceutical ecosystem gets right

When a woman is diagnosed with breast cancer in the United States today, her chances of surviving are much greater than in decades past — thanks to U.S. innovation. The incidence of breast cancer has increased by more than 200% globally in the past 40 years. But the U.S. mortality ...
Commentary

The rural hospital rescue fund is a fraud

Rural hospitals are supposedly in dire financial straits. And the forthcoming Medicaid “cuts” authorized by the One Big Beautiful Bill Act could put hundreds more facilities deep in the red. At least, that’s the prevailing narrative inside the beltway — and the justification for the $50 billion rural hospital “rescue” ...
Commentary

What’s The GLP-1 Black Market, How Big a Threat Is It?

A black market in weight-loss drugs is flourishing in plain sight. Rogue pharmacies and telehealth firms are flooding the United States with unauthorized knock-offs of semaglutide, tirzepatide, and other glucagon-like peptide-1 drugs. Better known by brand names like Ozempic, Wegovy, Mounjaro, and Zepbound, the knock-off versions of these drugs are ...
Commentary

Generics Must Compete On Price, Not Safety

America’s generic drug market is one of our greatest health policy successes. Today, 91% of all prescriptions in the U.S. are filled with generics. That dominance saves patients and taxpayers hundreds of billions of dollars every year—and it also drives innovation. Drugmakers know their monopoly on a new treatment will ...
Commentary

The Inflationary Effect of Drug Price Controls

In a bill chock full of bad policies, the drug pricing provision of the Inflation Reduction Act stands out as particularly troubling. This provision establishes a negotiation process to set a Maximum Fair Price (MFP) on selected drugs for Medicare patients. Because the legislation calls the MFP a negotiation doesn’t ...
Commentary

The Trump Administration Is Reviving Its Worst Drug Pricing Policies

It’s been a big year for revivals. There’s a new Jurassic Park movie, a reunion tour featuring 1990s rock band Oasis, and a Harry Potter television series in the works. President Trump is also looking to revive some of the policies he tried to enact during his first term. He ...
Commentary

Juvenile justice reforms drive a spike in criminal offenses

Juvenile crime in California is rising – and rising by a lot. Last year, the number of juveniles arrested for all types of offenses reached 32,874, which was a staggering increase of 70 percent from just a few years ago in 2021, and since 2019 juvenile homicides rose 82 percent. ...
Commentary

Is a Primary Care Revolution Dawning?

Americans in need of primary care will soon have more options, thanks to the One Big Beautiful Bill Act (OBBBA). The recently passed law allows patients to use money from tax-advantaged health savings accounts to pay for direct primary care for the first time. Direct primary care, or DPC, is ...
Scroll to Top